Search results
Results from the WOW.Com Content Network
Dopamine receptors are a class of G protein-coupled receptors that are prominent in the vertebrate central nervous system (CNS) and are implicated in many neurological processes, including motivational and incentive salience, cognition, memory, learning, and fine motor control, as well as modulation of neuroendocrine signaling.
The anticipation of most types of rewards increases the level of dopamine in the brain, [4] and many addictive drugs increase dopamine release or block its reuptake into neurons following release. [5] Other brain dopamine pathways are involved in motor control and in controlling the release of various
Salsolinol is a chemical compound derived from dopamine which plays a role in neurotransmission and is neurotoxic. It has been linked to dopamine-related disorders including Parkinson's disease and alcohol use disorder. It is both synthesized in the human body and ingested in several common dietary sources. [2]
Amphetamine, an NDRA and one of the most well-known DRAs. 4-Methylaminorex (4-MAR), the cis- isomer being one of the most dopamine-selective NDRAs known.. A dopamine releasing agent (DRA) is a type of drug which induces the release of dopamine in the body and/or brain.
Dopamine β-hydroxylase inhibitors like disulfiram (Antabuse), which can be used in the treatment of addiction to cocaine and similar dopaminergic drugs as a deterrent drug. The excess dopamine resulting from inhibition of the dopamine β-hydroxylase enzyme increases unpleasant symptoms such as anxiety, higher blood pressure, and restlessness.
The dopamine neurons of the dopaminergic pathways synthesize and release the neurotransmitter dopamine. [2] [3] Enzymes tyrosine hydroxylase and dopa decarboxylase are required for dopamine synthesis. [4] These enzymes are both produced in the cell bodies of dopamine neurons. Dopamine is stored in the cytoplasm and vesicles in axon terminals.
A dopamine reuptake inhibitor (DRI) is a class of drug which acts as a reuptake inhibitor of the monoamine neurotransmitter dopamine by blocking the action of the dopamine transporter (DAT). Reuptake inhibition is achieved when extracellular dopamine not absorbed by the postsynaptic neuron is blocked from re-entering the presynaptic neuron.
Dopamine agonists are often used in younger people as monotherapy and as initial therapy instead of L-DOPA. [7] Although it is important to know that there is a correlation between the two drugs, if l-DOPA doesn't work dopamine agonists are also ineffective. [1]